Human papillomavirus-related oropharyngeal cancer (HPV+) exhibited not only better response to treatment but also better survival, being generally associated to a good prognosis when compared to HPV-negative [3, 4], which lead to the adaptation of the eighth edition of the HNSCC tumour-node-metastasis (TNM) staging in order to include p16INK4A immunostaining as a surrogate for HPV status. The gene discussed is CDKN2A; the disease is neoplasm.